Loading patent…
AssigneeBraintree Laboratories, Inc.
InventorsEdmund V. Dennett JR., Robert M. Raleigh JR., Bruce H. Aronson
Estimating the term…
A composition for inhibiting gastrointestinal absorption of phosphorous in an individual dividual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.
A composition for binding phosphorous within the gastrointestinal tract of an individual, the composition comprising:
A composition for absorbing phosphorous within the gastrointestinal tract of an individual, the composition comprising approximately 667 mg of calcium acetate dimensioned to form a caplet for fitting within a volume defined by #0 size capsule in a manner which optimizes the volume of the capsule.
A composition for absorbing phosphorous within the gastrointestinal tract of an individual, the composition comprising approximately 333.5 mg of calcium acetate dimensioned to form a caplet for fitting within a volume defined by #2 size capsule in a manner which optimizes the volume of the capsule.
A method for binding phosphorous in the gastrointestinal tract of an individual, the method comprising at least the step of:
Dependencies are inferred from the claim text.